Fibroscan / VCTE Rate-of-Change Interpretation: What Your Score Means and How Fast It Should Move

What Fibroscan / VCTE Actually Measures

Fibroscan uses a 50-Hz mechanical pulse to propagate a shear wave through liver tissue. The device then uses ultrasound to track how fast that wave travels. Faster propagation means stiffer tissue; stiffer tissue reflects more collagen deposition. The result is expressed in kilopascals, a unit of pressure that correlates with liver fibrosis stage when calibrated against biopsy-confirmed histology.

The same probe simultaneously measures the Controlled Attenuation Parameter (CAP), reported in dB/m, which quantifies ultrasound attenuation caused by fat droplets. A single 10-minute exam therefore yields two independent biomarkers: fibrosis burden (kPa) and steatosis grade (dB/m). The combination makes VCTE one of the most information-dense non-invasive liver tests available in clinical practice today.

VCTE was validated in multiple biopsy-controlled cohorts. The landmark Ziol et al. Study (N=327, hepatitis C patients) established the foundational AUROC data showing that liver stiffness measurement (LSM) correlated with fibrosis stages F0, F4 with AUROCs ranging from 0.79 to 0.97 depending on the fibrosis stage being distinguished. [1] Subsequent MASLD-specific validation extended those findings to metabolic liver disease, the population most relevant to TRT, GLP-1, and longevity-medicine patients seen at HealthRX.

Technical Validity Requirements

A result is only reportable when the interquartile range-to-median ratio (IQR/M) is below 0.30 (i.e., <30%). The FDA-cleared labeling and EASL Clinical Practice Guidelines both specify this threshold. [2] If IQR/M exceeds 0.30, the exam should be repeated after a 2-hour fast and ideally after the patient has been supine and calm for 10 minutes.

Additional factors that artifactually raise kPa readings include: active hepatic inflammation (elevated ALT above 3× ULN), right-sided heart failure with hepatic congestion, and post-prandial state within 2 hours. Clinicians should review same-day ALT before interpreting a borderline result.

CAP Score Interpretation Alongside kPa

The EASL guidance from 2021 positions CAP scores in three bands: <248 dB/m (S0, S1, minimal steatosis), 248 to 267 dB/m (S1, S2, moderate steatosis), and ≥268 dB/m (S2, S3, severe steatosis). [2] A patient can have a normal kPa with a very high CAP, representing early MASLD without significant fibrosis. That pattern still warrants lifestyle intervention and metabolic optimization, even without pharmacologic fibrosis treatment.

VCTE Normal Range and Fibrosis Stage Cutoffs

The most widely cited MASLD-specific cutoffs come from the EASL Clinical Practice Guidelines on non-invasive tests (2021) and the AASLD Practice Guidance on NAFLD (2023, updated nomenclature to MASLD). [2,3] These guidelines converge on the following staging ladder.

F0, F1: No or Minimal Fibrosis

Liver stiffness below 7.0 kPa corresponds to F0 (no fibrosis) or F1 (mild portal fibrosis without septa) in MASLD patients with no active hepatitis. [3] A value in this range does not rule out steatosis, ballooning, or lobular inflammation. MASLD activity score can still be elevated even when the kPa is reassuring. Repeat VCTE in 24 months is appropriate for a stable low-risk patient.

F2: Significant Fibrosis

The 8.0 kPa threshold captures approximately F2 disease (periportal fibrosis with rare septa) with a positive predictive value of roughly 65 to 72% in MASLD cohorts. [3] The EASL 2021 guidance uses a "rule-in" cutoff of 8.0 kPa combined with other non-invasive markers such as the Fibrosis-4 (FIB-4) index. [2] Patients at F2 benefit from closer metabolic surveillance, aggressive steatohepatitis risk-factor management, and specialist referral depending on trajectory.

F3: Advanced Fibrosis

A reading at or above 12.0 kPa in a MASLD patient without confounding inflammation is consistent with F3 disease (bridging fibrosis). [3] This threshold carried an AUROC of 0.85 in the NASH CRN validation cohort (N=474 biopsy-confirmed MASLD patients). [4] F3 disease carries a meaningful risk of progression to cirrhosis within 5 to 10 years, and this stage now qualifies patients for resmetirom (Rezdiffra) under FDA-approved labeling.

F4: Cirrhosis

Values at or above 15.0 kPa are classified as probable cirrhosis by most guidelines, though some authorities use a lower threshold of 13.0 kPa. [2] A 2022 meta-analysis by Petroff et al. (N=6,212 across 17 studies) reported a pooled AUROC of 0.89 (95% CI: 0.87 to 0.91) for VCTE detecting cirrhosis in MASLD populations. [5] Patients at this stage require hepatology co-management, surveillance upper endoscopy for varices, and semi-annual HCC surveillance with ultrasound plus AFP.

Rate-of-Change Interpretation: What Constitutes Meaningful Progression or Regression

A single kPa number in isolation is informative. Serial kPa values over time, however, are where VCTE delivers its greatest clinical value. The concept of "rate of change" refers to the percentage shift in LSM between two adequately valid exams taken at a defined interval.

Defining Clinically Significant Change

The EASL/EASL-ALEH joint 2021 statement on non-invasive fibrosis biomarkers defines a ≥20% increase in LSM over 12 months as a signal of progressing fibrosis warranting treatment escalation or biopsy re-evaluation. [2] Conversely, a ≥30% decrease in LSM over 12 to 18 months is accepted as evidence of fibrosis regression, a threshold used as a secondary endpoint in several Phase 3 MASLD trials.

The REGENERATE trial of obeticholic acid (N=931 biopsy-confirmed NASH, F2, F3) used a one-stage improvement in NASH CRN fibrosis score as its histologic endpoint, and VCTE changes tracked with those biopsy changes at 18 months: patients with ≥20% LSM reduction had a 2.4-fold higher probability of histologic fibrosis improvement compared with those whose LSM was stable or rising. [6]

A practical clinical framework for HealthRX patients on serial VCTE monitoring:

| LSM Change at 12 Months | Interpretation | Suggested Action | |---|---|---| | Decrease ≥30% | Probable fibrosis regression | Continue current regimen; re-test at 12 to 24 months | | Decrease 10 to 29% | Possible improvement; trend favorable | Re-test at 12 months; optimize metabolic risk factors | | Change <10% | Stable disease | Continue monitoring; re-test at 12 to 24 months | | Increase 10 to 19% | Early progression signal | Review ALT for inflammation; tighten metabolic control | | Increase ≥20% | Probable fibrosis progression | Escalate treatment; consider biopsy or specialist referral |

Confounders That Mimic Progression or Regression

A spike in LSM can occur without true fibrosis progression if the patient had a fatty meal within 2 hours of the exam, consumed alcohol within 24 hours, or presented with an ALT flare from any cause. The 2021 EASL guidance explicitly states: "LSM should not be interpreted in isolation and must be contextualized with ALT, BMI trajectory, and other non-invasive fibrosis markers such as FIB-4." [2] A 20% apparent increase in kPa alongside a 3× ULN ALT elevation may represent acute hepatocellular inflammation rather than structural fibrosis progression. Repeating the exam after ALT normalization resolves the ambiguity.

Body weight is another powerful confounder. Weight loss of 10% or more lowers liver stiffness independent of true fibrosis regression, as demonstrated in a bariatric surgery cohort (N=88) where LSM fell by a median of 3.1 kPa at 12 months post-sleeve gastrectomy even in patients whose paired biopsy showed stable fibrosis stage. [7] GLP-1 receptor agonist-driven weight loss produces a similar effect. Clinicians at HealthRX prescribing semaglutide 2.4 mg (Wegovy) alongside VCTE monitoring should factor in the 10 to 15% mean body weight reduction reported in STEP-1 (N=1,961) when interpreting a large LSM drop. [8]

Re-Testing Intervals by Fibrosis Stage

The AASLD 2023 guidance recommends re-testing intervals calibrated to baseline fibrosis burden. [3] Patients with F0, F1 disease (LSM <7.0 kPa) and well-controlled metabolic risk factors may safely extend monitoring to every 24 months. Those with F2 disease (8.0 to 11.9 kPa) warrant annual VCTE. Patients at F3 (12.0 to 14.9 kPa) should be re-tested every 6 to 12 months, especially during active treatment with resmetirom or a GLP-1/GIP dual agonist.

MASLD Staging and Resmetirom Prescribing Criteria

MASLD Diagnostic Criteria Using VCTE

MASLD replaces the older term NAFLD following the 2023 Delphi consensus. [9] The condition is defined by hepatic steatosis (CAP ≥268 dB/m on VCTE, or equivalent imaging or biopsy evidence) combined with at least one of five cardiometabolic risk factors: BMI ≥25 kg/m², fasting glucose ≥100 mg/dL, blood pressure ≥130/85 mmHg, triglycerides ≥150 mg/dL, or HDL-C below 40 mg/dL (men) / 50 mg/dL (women). The presence of significant alcohol intake reclassifies the condition as ALD or MetALD. Accurate MASLD diagnosis requires VCTE as a non-invasive screening step before escalating to biopsy.

Resmetirom (Rezdiffra): FDA-Approved March 2024

Resmetirom became the first FDA-approved pharmacotherapy for MASLD-associated fibrosis in March 2024. [10] The MAESTRO-NASH trial (N=966 biopsy-confirmed MASH, F2, F3) demonstrated fibrosis improvement of at least one stage without worsening of MASH in 26% of patients receiving resmetirom 80 mg versus 14% of placebo-treated patients (P<0.001). [11] The 100 mg dose achieved a 26% response versus 14% placebo (P<0.001) on the same endpoint.

FDA-approved prescribing criteria require a VCTE reading of ≥8.2 kPa at screening, consistent with at least F2 disease, alongside biopsy confirmation of MASH with F2, F3 fibrosis. VCTE thus serves a gating function in resmetirom candidacy: patients who test below 8.2 kPa are unlikely to meet biopsy criteria and are not candidates for the drug at that time.

The FDA prescribing information for resmetirom specifies the 80 mg dose for body weight <100 kg and the 100 mg dose for body weight ≥100 kg. [10] Both doses are taken orally once daily with or without food.

GLP-1 and GLP-1/GIP Agonists in MASLD

Semaglutide 2.4 mg (Wegovy / Ozempic) and tirzepatide (Mounjaro / Zepbound) are not FDA-approved specifically for MASLD as of mid-2025, but clinical trial data are compelling. The ESSENCE trial of semaglutide 2.4 mg subcutaneous once weekly in MASH (F2, F3) reported that 63% of semaglutide-treated patients achieved MASH resolution without worsening fibrosis versus 34% of placebo-treated patients at 72 weeks. [12] LSM change on VCTE was a pre-specified secondary endpoint, with mean LSM reduction of 2.8 kPa in the semaglutide group versus 0.7 kPa in placebo. These data position VCTE as a monitoring tool during GLP-1 therapy even before a formal MASLD indication exists.

Optimal Fibroscan / VCTE Target: What to Aim For

"Optimal" differs from "normal" in longevity medicine. Normal means below the disease threshold. Optimal means tracking toward the lowest achievable burden consistent with age and metabolic health.

Population Reference Data

A 2019 population-based study by de Lédinghen et al. Using paired VCTE data from 10,234 healthy adults without liver disease, excessive alcohol use, or known metabolic syndrome found a median LSM of 4.8 kPa (IQR: 4.1 to 5.7 kPa) in adults aged 40 to 60. [13] This benchmark represents a reasonable "optimal" LSM target for metabolically healthy patients undergoing longevity monitoring. Patients on HealthRX TRT or GLP-1 programs should aim to maintain LSM below 5.5 kPa if their baseline is in the normal range, or to achieve progressive movement toward 5.5 kPa if their baseline is elevated.

TRT and Liver Stiffness

Testosterone replacement therapy has not been shown to worsen liver stiffness at physiologic doses delivered via transdermal or injectable routes. A 2020 review in the Journal of Clinical Endocrinology and Metabolism found no signal of fibrosis progression associated with injectable testosterone cypionate or enanthate at doses maintaining serum testosterone in the 400 to 900 ng/dL range. [14] Oral 17-alpha-alkylated androgens carry documented hepatotoxicity risk and are not prescribed in evidence-based TRT programs. Patients on transdermal or injectable TRT at HealthRX who have baseline MASLD should still receive annual VCTE monitoring given the high co-prevalence of metabolic syndrome and MASLD in the TRT-seeking population.

The FIB-4 + VCTE Sequential Algorithm

The EASL/EASL-ALEH 2021 guidance recommends a two-step algorithm: FIB-4 as a cheap, widely available first-pass filter, followed by VCTE for those with FIB-4 in the indeterminate zone (1.30 to 2.67). [2] A FIB-4 <1.30 in a patient under age 65 has a negative predictive value of approximately 90% for advanced fibrosis, potentially allowing VCTE to be deferred. A FIB-4 ≥2.67 warrants direct VCTE and hepatology referral regardless of age.

The AASLD 2023 guidance endorsed the same sequential approach, noting: "The combination of FIB-4 and LSM by VCTE correctly reclassifies approximately 40% of patients in the indeterminate FIB-4 zone and should be used as the standard non-invasive pathway before liver biopsy." [3]

Practical Monitoring Protocol for HealthRX Patients

Patients presenting to HealthRX with suspected or confirmed MASLD should follow a structured VCTE monitoring protocol informed by their baseline fibrosis stage, concurrent therapies, and trajectory of cardiometabolic risk factors.

Baseline Assessment

Before the first VCTE, obtain: fasting lipid panel, fasting glucose and HbA1c, ALT and AST, platelet count (for FIB-4 calculation), and BMI. Calculate FIB-4. If FIB-4 is ≥1.30, proceed to VCTE. If FIB-4 is <1.30 in a patient under 65 with no red-flag symptoms, re-check FIB-4 annually before deciding whether to add VCTE.

The exam must be performed after a 2-hour fast. The patient should rest supine for at least 10 minutes before measurement. Document the IQR/M ratio with every result. Any result with IQR/M ≥0.30 should be flagged and repeated.

Monitoring Schedule by Stage

Patients at F0, F1 (LSM <7.0 kPa) with stable metabolic parameters: repeat VCTE in 24 months. Patients at F2 (8.0 to 11.9 kPa): repeat VCTE in 12 months with concurrent FIB-4 and ALT review. Patients at F3 (≥12.0 kPa): repeat VCTE every 6 to 12 months; refer to hepatology; discuss resmetirom candidacy and biopsy planning. Patients at F4 (≥15.0 kPa): hepatology-led care; VCTE every 6 months; HCC surveillance with abdominal ultrasound plus AFP every 6 months per AASLD guidance. [3]

Interpreting a Falling kPa During GLP-1 Therapy

A patient starting semaglutide 2.4 mg who loses 12% of body weight over 6 months may show a 1.5 to 3.0 kPa LSM reduction at the next VCTE. Whether that drop reflects true fibrosis regression or simply reduced hepatic congestion and steatosis requires longitudinal tracking across at least two post-treatment VCTE exams. A ≥30% LSM reduction sustained across two consecutive annual exams, alongside normalization of ALT and FIB-4, provides strong non-invasive evidence of genuine fibrosis regression. That threshold, rather than a single favorable scan, should guide decisions about reducing monitoring frequency.